Genomic-Driven Precision Oncology With Next Generation Sequencing Testing
Comprehensive genomic testing with next-generation sequencing (NGS) can inform clinicians with valuable insights into available genomic-based targeted treatments and immunotherapies for cancer patients. However, implementing an effective and well-organized clinical precision oncology program can be challenging due to ever-growing and ever-changing molecular testing and treatment standards. This presentation will describe key components of precision cancer medicine: NGS testing, Molecular-Tumor-Board, and a review of 2021 FDA-approved new oncologic drugs. The presentation will conclude with a case study in precision oncology with a lung cancer patient with brain metastasis.
Originally published on March 6, 2023
Jong Taek Kim, MD, MSAssistant Professor of Pathology
University of Utah School of Medicine
Medical Director, Molecular Oncology